17 completed, 1 active not recruiting, 1 terminated. 19 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 17, Active not recruiting 1, Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Haemophilus Influenzae Type b: new trials by email Literature Review of Haemophilus Influenzae Type b trials Research Report on Haemophilus Influenzae Type b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
| Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa, Prevenar 13, GSK217744 - Acellular Pertussis, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 657 | 2011-10-14 | 2020-07-17 |
| Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa™, Prevenar 13®, GSK217744 - Tetanus, Poliomyelitis | Phase 2 | Completed | GlaxoSmithKline | 721 | 2010-12-09 | 2018-08-20 |
| Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose GSK2202083A vaccine, Infanrix hexa™, Menjugate™ - Tetanus, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 391 | 2010-08-18 | 2020-01-21 |
| Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants GSK2202083A vaccine, Prevenar 13®, Infanrix hexa™ - Tetanus, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 480 | 2010-05-17 | 2018-08-20 |
| Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers GSK2036874A vaccine, Zilbrix™/Hib vaccine, Poliorix™ - Haemophilus Influenzae Type b, Tetanus | Phase 2 | Completed | GlaxoSmithKline | 312 | 2010-05-13 | 2019-10-01 |
| Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age GSK2202083A vaccine, 10-valent pneumococcal vaccine (GSK 1024850A), Infanrix hexa™ - Tetanus, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 421 | 2009-08-13 | 2020-01-03 |
| Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants GSK2197870A, Prevenar™, Menitorix™ - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 2 | Completed | GlaxoSmithKline | 284 | 2009-06-24 | 2018-06-06 |
| Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. GSK2202083A vaccine, Infanrix hexa, Menjugate - Tetanus, Poliomyelitis | Phase 2 | Terminated | GlaxoSmithKline | 16 | 2009-04-01 | 2018-06-06 |
| Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine Infanrix Hexa - Acellular Pertussis, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 403 | 2008-02-01 | 2018-06-06 |
| Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age Infanrix hexa Vaccine - Acellular Pertussis, Tetanus | Phase 2 | Completed | GlaxoSmithKline | 450 | 2006-10-01 | 2016-11-04 |
| Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 Pneumococcal (vaccine) - Acellular Pertussis, Tetanus | Phase 2 | Completed | GlaxoSmithKline | 689 | 2005-11-01 | 2016-09-23 |
| Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines MenHibrix (Hib-MenCY-TT), Infanrix® Penta, Prevenar® - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 2 | Completed | GlaxoSmithKline | 1104 | 2005-04-11 | 2018-07-19 |
| Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants DTaP-IPV-HB-PRP~T, DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine - Diphtheria, Tetanus | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 624 | 2004-10-01 | 2013-12-17 |
| Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 2 | Completed | GlaxoSmithKline | 756 | 2004-08-01 | 2018-08-24 |
| Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™ Tritanrix™-HepB low thio /, Hib 2.5, Tritanrix™-HepB - Haemophilus Influenzae Type b | Phase 2 | Completed | GlaxoSmithKline | 192 | 2003-08-01 | 2016-09-09 |
| A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. DTPw-HBV/Hib-MenAC conjugate vaccine - Haemophilus Influenzae Type b, Tetanus | Phase 2 | Completed | GlaxoSmithKline | 450 | 2003-07-01 | 2016-09-09 |
| Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine Hib-MenCY-TT vaccine (MenHibrix), Meningitec®, ActHIB® - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 2 | Completed | GlaxoSmithKline | 409 | 2003-03-01 | 2018-08-27 |
| 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age Hib-MenCY-TT vaccine, Hib-MenC-TT vaccine, Menjugate ® - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 2 | Completed | GlaxoSmithKline | 388 | 2003-03-01 | 2018-08-27 |
Haemophilus Infections (19) · Diphtheria (14) · Hepatitis B (14) · Tetanus (14) · Poliomyelitis (11) · Whooping Cough (3) · Meningococcal Infections (1)
Bacterial Infections (19) · Bacterial Infections and Mycoses (19) · Gram-Negative Bacterial Infections (19) · Infections (19) · Pasteurellaceae Infections (19) · Actinomycetales Infections (14) · Blood-Borne Infections (14) · Clostridium Infections (14) · Communicable Diseases (14) · Corynebacterium Infections (14) · DNA Virus Infections (14) · Digestive System Diseases (14) · Gram-Positive Bacterial Infections (14) · Hepadnaviridae Infections (14) · Hepatitis (14)
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (9) · Heptavalent Pneumococcal Conjugate Vaccine (4) · 13-valent pneumococcal vaccine (3) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (3) · Hib-MenCY-TT vaccine (3) · DTPa-HBV-IPV combined vaccine (2) · 10-valent pneumococcal vaccine (1) · Chickenpox Vaccine (1) · DTP-IPV-Hib vaccine (1) · DTaP-IPV-HB-PRP-T vaccine (1) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (1) · Hiberix (1) · Meningococcal Vaccines (1) · PEDIARIX (1) · PHiD-CV vaccine (1)
GlaxoSmithKline (17) · LG Chem (1) · Sanofi Pasteur, a Sanofi Company (1)
Finland (4) · Philippines (4) · Germany (3) · Australia (2) · Dominican Republic (2) · Poland (2) · Argentina (1) · Belgium (1) · Canada (1) · France (1) · Slovakia (1) · United Kingdom (1) · United States (1)
PMID 28340322, PMID 20657177, PMID 21372751
2009 (1), 2016 (1)